Ignite Creation Date:
2024-05-05 @ 11:30 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00063401
Status:
COMPLETED
Last Update Posted:
2010-04-08
First Post:
2003-06-25
Brief Title:
Phase II Study in Patients With Epidermal Growth Factor Receptor EGFR Advanced Stage Ovarian Primary Peritoneal and Fallopian Tube Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Phase II Study of Cetuximab C225PaclitaxelCarboplatin for the Initial Treatment of Advanced Stage Ovarian Primary Peritoneal and Fallopian Tube Cancer
Status:
COMPLETED
Status Verified Date:
2010-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to determine the progression-free survival obtained with cetuximab C225paclitaxelcarboplatin in subjects with newly diagnosed advanced stage ovarian primary peritoneal or fallopian tube cancer
Detailed Description:
The population being studied in this trial is subjects with advanced stage ovarian primary peritoneal and fallopian tube cancer will be enrolled By receiving combination therapy with cetuximab C225paclitaxelcarboplatin these subjects will experience longer progression-free survival than previously reported for subjects receiving only paclitaxel and carboplatin
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None